Yahoo
NasdaqGS - Delayed Quote USD

Boundless Bio, Inc. (BOLD)

2.4700 -0.0100 (-0.40%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for BOLD
  • Previous Close 2.4800
  • Open 2.5250
  • Bid 2.3900 x 100
  • Ask 2.5100 x 100
  • Day's Range 2.4300 - 2.5900
  • 52 Week Range 0.9610 - 3.1640
  • Volume 47,014
  • Avg. Volume 178,100
  • Market Cap (intraday) 57.079M
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) --
  • EPS (TTM) -2.8500
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 4.00

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

boundlessbio.com

28

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BOLD
105.83%
S&P 500 (^GSPC)
10.73%

1-Year Return

BOLD
78.99%
S&P 500 (^GSPC)
11.11%

3-Year Return

BOLD
82.67%
S&P 500 (^GSPC)
81.91%

5-Year Return

BOLD
82.67%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -23.69M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

4.00
4.00 Average
2.4700 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/11/2025
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 5 -> 4

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.77%

  • Return on Equity (ttm)

    -67.86%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -64.01M

  • Diluted EPS (ttm)

    -2.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    72.63M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -30.55M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: